Business
BullFrog AI Announces Issuance of U.S. Patent Protecting Novel Prodrugs of Mebendazole and Their Use in Treating Cancer
Novel compounds show improved bioavailability relative to mebendazole GAITHERSBURG, Md., July 25, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:
About this update from Bullfrog Ai Holdings, Inc.
[{"type":"text","content":"Novel compounds show improved bioavailability relative to mebendazole\nGAITHERSBURG, Md., July 25, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) (\"BullFrog AI\" or the \"Company\"), a precision medicine company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced that the United States Patent and Trademark Office (USPTO) will, on August 1, 2023, issue U.S. Patent No. 11,712,435 protecting the Company’s novel prodrugs derived from mebendazole and their use in treating cancers and other diseases. The patented compounds exhibit improved solubility and oral bioavailability relative to the parent drug, thereby addressing a key difficulty encountered in evaluating the potential use of mebendazole for oncology indications. U.S. Patent No. 11,712,435 represents the first issued patent resulting from intellectual property BullFrog AI licensed from Johns Hopkins University in October 2022. BullFrog AI’s exclusive, worldwide, royalty-bearing license includes the rights to commercialize prodrugs of mebendazole that demonstrate improved solubility and bioavailability relative to the parent compound. \"This patent grant further strengthens intellectual property protection of our carefully curated and strategically acquired licensed product portfolio,\" said Vin Singh, founder and CEO of BullFrog AI. \"Mebendazole has shown promise in treating various types of cancer, and these N-substituted prodrugs of mebendazole demonstrate significantly improved solubility and bioavailability relative to the parent compound, enhancing their therapeutic potential and improving the likelihood of clinical success. We look forward to working with strategic partners to monetize this promising asset for the treatment of glioblastoma and other oncology indications.\" About BullFrog AI BullFrog AI is a precision medicine company using AI and machine learning to enable the successful development of pharmaceuticals and biologics by predicting which patients will respond to therapies in development. Through its collaborations with leading research institutions, including Johns Hopkins University, BullFrog AI is at the forefront of AI-driven drug development using its proprietary bfLEAP™ artificial intelligence platform. BullFrog AI is deploying bfLEA...